Neumora Therapeutics/$NMRA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Neumora Therapeutics

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Ticker

$NMRA
Sector
Health
Primary listing
NASDAQ

Employees

96
Headquarters
Watertown, United States
Website
www.neumoratx.com

NMRA Metrics

BasicAdvanced
$426M
-
-$1.57
-
-

Bulls say / Bears say

Closed a $125 million venture debt agreement, with $20 million already received and another $20 million available in 2025, extending the cash runway through 2027 to support operations through several key clinical milestones (Reuters).
Progressing with a robust pipeline of seven neuroscience programs, including Phase 3 navacaprant and Phase 1b NMRA-511, with topline NMRA-511 data expected by late 2025 and navacaprant KOASTAL-3 results due in Q1 2026 (Reuters).
The K2 HealthVentures debt facility uses a non-dilutive structure, protecting shareholder equity and strengthening the balance sheet for ongoing R&D investment (Reuters).
Net loss increased to $68.0 million in Q1 2025, compared to $53.7 million in the prior year, reflecting a higher cash burn with no revenue being generated (Reuters).
Received a Nasdaq non-compliance notice on May 14, 2025 for not maintaining the $1 minimum bid price; the company has 180 days to correct the issue or risk delisting, and there is ongoing uncertainty regarding any potential reverse stock split (Reuters).
Pivotal topline results for KOASTAL-3 and -2 Phase 3 navacaprant studies are now anticipated in Q1 and Q2 2026, leaving the stock exposed to extended timeline risks and depending on distant milestones (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 11 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NMRA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs